Posted by Michael Wonder on 19 Jul 2021
Lilly and Incyte provide update on supplemental new drug application for baricitinib for the treatment of moderate to severe atopic dermatitis
16 July 2021 - Eli Lilly and Incyte announced today that the U.S. FDA will not meet the Prescription Drug User Fee Act action date for the supplemental new drug application for baricitinib for the treatment of adults with moderate to severe atopic dermatitis.
The delay is related to the FDA's on-going assessment of JAK inhibitors.
